In addition, mTOR inhibitors have been used in combination with chemotherapy regiments for the treatment of relapse ALL (Santiago et al., 2017), and bcl‐2 inhibitors have also been used in the treatment for all subtypes of pediatric ALL (Jones et al., 2016). This evidence concerns the gene BCL2 and acute lymphoblastic leukemia.